PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy

• Published in: Journal of cellular physiology Vol. 234; no. 10; pp. 16824 - 16837
• Main Authors: Salmaninejad, Arash, Valilou, Saeed Farajzadeh, Shabgah, Arezoo Gowhari, Aslani, Saeed, Alimardani, Malihe, Pasdar, Alireza, Sahebkar, Amirhossein
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2019
• Subjects: Antigens; Antitumor activity; Apoptosis; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Biomarkers; Cancer; Cancer immunotherapy; cancer therapy; Cell death; Clinical trials; Gene Expression Regulation, Neoplastic; Humans; Immune checkpoint; Immunological tolerance; Immunoregulation; Immunotherapy; Lymphocytes; Lymphocytes T; Medical research; Monoclonal antibodies; monoclonal antibody; Neoplasms - therapy; PD-L1 protein; PD‐1; PD‐L‐1; Programmed Cell Death 1 Receptor - genetics; Programmed Cell Death 1 Receptor - metabolism; Survival; PD-L-1; cancer therapy; monoclonal antibody; PD-1; immune checkpoint

Over the course of past few years, cancer immunotherapy has been accompanied with promising results. However, preliminary investigations with respect to immunotherapy concentrated mostly on targeting the immune checkpoints, nowadays, emerge as the most efficient strategy to raise beneficial antitumo...